BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Lazarus JV, Cortez-Pinto H, Anstee QM. Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". J Hepatol 2020;73:221-2. [PMID: 32280051 DOI: 10.1016/j.jhep.2020.03.017] [Reference Citation Analysis]
2 Palayew A, Stumo SR, Cooke GS, Hutchinson SJ, Jauffret-Roustide M, Maticic M, Harris M, Metwally AM, Razavi H, Lazarus JV; Hep-CORE Study Group. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS One 2020;15:e0235715. [PMID: 32722701 DOI: 10.1371/journal.pone.0235715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726. [PMID: 31189677 DOI: 10.1136/bmjopen-2018-026726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
4 Gupta G, Yakubu I, Zhang Y, Kimball P, Kang L, Mitchell K, Ijioma S, Carroll N, Patterson J, Shinbashi M, Kumar D, Moinuddin I, Kamal L, King A, Bhati C, Levy M, Cotterell A, Khan A, Sharma A, Sterling R. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transplant 2021. [PMID: 34212479 DOI: 10.1111/ajt.16747] [Reference Citation Analysis]
5 Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy 2020;86:102964. [DOI: 10.1016/j.drugpo.2020.102964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Momayyezi M, Fallahzadeh H, Farzaneh F, Momayyezi M. Sleep Quality and Cancer-Related Fatigue in Patients with Cancer. J Caring Sci 2021;10:145-52. [PMID: 34849358 DOI: 10.34172/jcs.2021.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, Somaini L, Mulvihill E, Ertl J, Grebely J. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study. J Viral Hepat 2019;26:1094-104. [PMID: 31074167 DOI: 10.1111/jvh.13119] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
8 Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc ÖM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, Peerlinck K, Apers L, Robaeys G, Lazarus JV. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis 2020;20:181. [PMID: 32106819 DOI: 10.1186/s12879-020-4898-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J, Grebely J, Dore G, Dalgard O, Bruggmann P, Stedman C, Lacombe K, Powis J, Hellard M, Crawford S, Swan T, Byrne J, Lacalamita M, Cunningham E, Hajarizadeh B, Grebely J, Dore G, Marks P, Shaw I, Siriragavan S, Amin J, Quiene S, Petoumenos K, Schmid P, Castro E, Moriggia A, Lacombe K, Daulouede J, Dalgard O, Conway B, Fraser C, Powis J, Feld J, Bruneau J, Cooper C, Gane E, Stedman C, Matthews G, Dunlop A, Hellard M, Kronborg I, Shaw D, Litwin A, Thurnheer MC, Weltman M, Read P, Dillon J, Kessler S, Knapp C, Oprandi L, Messina P, Pantic M, Cam ML, Maitre C, Andreassen J, Melkeraaen I, Tollefsen MM, Pagarigan H, Milne R, Mason K, Kaznowski D, Zou L, Bouchard R, Kotsoros B, Muir M, Milloy J, Oliver V, Noonan T, Sevehon A, Hazelwood S, Hall M, Hagenauer M, Liddle R, Ferguson C, Agyemang L, Patel H, Soloway I, Cerocchi O, Lacalamita M, Fragomeli V, Gilliver R, Lothian R, Cleary S, Johnston L, Middleton S, Brainard D, Mchutchison J, Grebely J, Dore G, Dalgard O, Bruggmann P, Stedman C, Lacombe K, Powis J, Hellard M, Crawford S, Swan T, Byrne J, Lacalamita M, Cunningham E, Hajarizadeh B, Grebely J, Dore G, Marks P, Shaw I, Siriragavan S, Amin J, Quiene S, Petoumenos K, Schmid P, Castro E, Moriggia A, Lacombe K, Daulouede J, Dalgard O, Conway B, Fraser C, Powis J, Feld J, Bruneau J, Cooper C, Gane E, Stedman C, Matthews G, Dunlop A, Hellard M, Kronborg I, Shaw D, Litwin A, Thurnheer MC, Weltman M, Read P, Dillon J, Kessler S, Knapp C, Oprandi L, Messina P, Pantic M, Cam ML, Maitre C, Andreassen J, Melkeraaen I, Tollefsen MM, Pagarigan H, Milne R, Mason K, Kaznowski D, Zou L, Bouchard R, Kotsoros B, Muir M, Milloy J, Oliver V, Noonan T, Sevehon A, Hazelwood S, Hall M, Hagenauer M, Liddle R, Ferguson C, Agyemang L, Patel H, Soloway I, Cerocchi O, Lacalamita M, Fragomeli V, Gilliver R, Lothian R, Cleary S, Johnston L, Middleton S, Brainard D, Mchutchison J; SIMPLIFY and D3FEAT study groups. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical Infectious Diseases 2020;71:e115-24. [DOI: 10.1093/cid/ciz1089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
10 Kåberg M, Edgren E, Hammarberg A, Weiland O. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity. Scand J Gastroenterol 2019;54:319-27. [PMID: 30907178 DOI: 10.1080/00365521.2019.1580764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Cortesi PA, Barca R, Giudicatti G, Mossini S, Ciaccio A, Iannazzo S, Micale M, Cesana G, Mantovani LG. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. Aliment Pharmacol Ther 2019;49:1126-33. [PMID: 30843268 DOI: 10.1111/apt.15201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
12 Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Rev Med Virol 2019;29:e2075. [PMID: 31322806 DOI: 10.1002/rmv.2075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Cammarota S, Citarella A, Guida A, Conti V, Iannaccone T, Flacco ME, Bravi F, Naccarato C, Piscitelli A, Piscitelli R, Valente A, Calella G, Coppola N, Parruti G. The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study). PLoS One 2019;14:e0219396. [PMID: 31291351 DOI: 10.1371/journal.pone.0219396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
15 Wade AJ. Can community pharmacists treat hepatitis C virus? Lancet Gastroenterol Hepatol 2020;5:790-1. [PMID: 32526211 DOI: 10.1016/S2468-1253(20)30184-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. Drug Alcohol Depend 2020;206:107705. [PMID: 31718924 DOI: 10.1016/j.drugalcdep.2019.107705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
17 Marshall AD, Madden A, Treloar C. Enhancing engagement in hepatitis C care among people who inject drugs. Addiction 2019;114:2104-6. [DOI: 10.1111/add.14698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Wang J, Qu B, Zhang F, Zhang C, Deng W, Dao Thi VL, Xia Y. Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. Stem Cells Int 2019;2019:9605252. [PMID: 31281392 DOI: 10.1155/2019/9605252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Alotaibi AS, Shamas N, Ansari UU, Sanai FM, Alshahrani A, Fathelrahman AI, Aseeri MA. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia. J Pharm Bioallied Sci 2021;13:317-24. [PMID: 35017888 DOI: 10.4103/jpbs.jpbs_166_21] [Reference Citation Analysis]
20 Sacks-Davis R, van Santen DK, Doyle JS. Commentary on Barré et al. (2020): Identifying remaining barriers to hepatitis C treatment in the DAA era. Addiction 2020;115:583-4. [PMID: 31885116 DOI: 10.1111/add.14887] [Reference Citation Analysis]
21 Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int 2020;40:51-9. [PMID: 31509639 DOI: 10.1111/liv.14247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Rand LZ, Kesselheim AS. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles. J Law Med Ethics 2020;48:583-94. [PMID: 33021189 DOI: 10.1177/1073110520958885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Coinfection Cohort Study Investigators. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis 2020;71:363-71. [PMID: 31504327 DOI: 10.1093/cid/ciz833] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
24 Pericàs JM, Bromberg DJ, Ocampo D, Schatz E, Wawer I, Wysocki P, Safreed-Harmon K, Lazarus JV. Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J 2019;16:20. [PMID: 30898122 DOI: 10.1186/s12954-019-0290-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, Hens N, Matheï C, Robaeys G. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J 2021;18:54. [PMID: 34001145 DOI: 10.1186/s12954-021-00502-7] [Reference Citation Analysis]
26 Busschots D, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Janssens F, Van den Bergh L, Van Lint P, Bruckers L, Nevens F, Robaeys G. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era. BMC Public Health 2021;21:1574. [PMID: 34416867 DOI: 10.1186/s12889-021-11608-9] [Reference Citation Analysis]
27 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
28 Palayew A, Razavi H, Hutchinson SJ, Cooke GS, Lazarus JV. Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? Lancet Gastroenterol Hepatol 2020;5:948-53. [PMID: 32730784 DOI: 10.1016/S2468-1253(20)30011-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. Clin Mol Hepatol 2021;27:474-85. [PMID: 33601868 DOI: 10.3350/cmh.2021.0015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Lazarus JV, Palayew A, van Damme P, Hendrickx G, Peck R, Colombo M. Eliminating hepatitis C in Europe. The Lancet Gastroenterology & Hepatology 2019;4:335-6. [DOI: 10.1016/s2468-1253(19)30082-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Schmidbauer C, Schwarz M, Schütz A, Schubert R, Schwanke C, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. PLoS One 2021;16:e0252274. [PMID: 34086708 DOI: 10.1371/journal.pone.0252274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. PLoS One 2020;15:e0229239. [PMID: 32155165 DOI: 10.1371/journal.pone.0229239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Janjua NZ, Wong S, Darvishian M, Butt ZA, Yu A, Binka M, Alvarez M, Woods R, Yoshida EM, Ramji A, Feld J, Krajden M. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat. 2020;27:781-793. [PMID: 32187430 DOI: 10.1111/jvh.13295] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
34 Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet 2020;139:855-63. [PMID: 32100095 DOI: 10.1007/s00439-020-02136-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Goldstein ND, Kahal D, Testa K, Burstyn I. Inverse probability weighting for selection bias in a Delaware community health center electronic medical record study of community deprivation and hepatitis C prevalence. Ann Epidemiol 2021;60:1-7. [PMID: 33933628 DOI: 10.1016/j.annepidem.2021.04.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, Fontaine G, Conway A, Valencia BM, Bajis S, Presseau J, Ward JW, Degenhardt L, Dore GJ, Hickman M, Vickerman P, Grebely J. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022:S2468-1253(21)00471-4. [PMID: 35303490 DOI: 10.1016/S2468-1253(21)00471-4] [Reference Citation Analysis]
37 Schmidbauer C, Chromy D, Schmidbauer V, Bauer D, Apata M, Nguyen D, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int 2020;40:787-96. [PMID: 32017359 DOI: 10.1111/liv.14399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, Andrews-Joseph A, Alam A, Ferreira-Gonzalez A, Kumar D, Moinuddin IK, Kamal L, King AL, Levy M, Sharma A, Cotterell A, Reichman TW, Khan A, Kimball P, Stiltner R, Baldecchi M, Brigle N, Gehr T, Sterling RK. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant 2020;20:739-51. [PMID: 31652392 DOI: 10.1111/ajt.15664] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
39 Amaddeo G, Nguyen CT, Maillé P, Mulé S, Luciani A, Machou C, Rodrigues A, Regnault H, Mallat A, Laurent A, Lafdil F, Hézode C, Pawlotsky JM, Calderaro J. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. Liver Int 2020;40:74-82. [PMID: 31444947 DOI: 10.1111/liv.14226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
40 Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, Mclean E, Trooskin S, Treloar C, Grebely J. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. International Journal of Drug Policy 2019;66:87-93. [DOI: 10.1016/j.drugpo.2019.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
41 Grubert Van Iderstine M, Iluz-Freundlich D, Dolovich C, Villarin E, Minuk GY. Liver disease referrals to an urban, hospital-based hepatology outpatient clinic over the past 25 years. JGH Open 2020;4:484-9. [PMID: 32514458 DOI: 10.1002/jgh3.12286] [Reference Citation Analysis]
42 Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis 2019;19:1019. [PMID: 31791253 DOI: 10.1186/s12879-019-4524-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
43 van Dijk M, Drenth JPH; HepNed study group. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination. J Viral Hepat 2020;27:1270-83. [PMID: 32964615 DOI: 10.1111/jvh.13399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Huiban L, Stanciu C, Muzica CM, Cuciureanu T, Chiriac S, Zenovia S, Burduloi VM, Petrea O, Sîngeap AM, Gîrleanu I, Sfarti C, Cojocariu C, Trifan A. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. Healthcare (Basel) 2021;9:651. [PMID: 34072635 DOI: 10.3390/healthcare9060651] [Reference Citation Analysis]
45 Miranda AC, Mendez J, Serrão R, Vale F, Manata MJ, Pinto S, Gomes A, Valente C, Pacheco P, Pazos R, Pereira R, Martins A, Germano I, Rocha S, Reis AP, Sarmento-Castro R. Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group). J Viral Hepat 2020;27:715-20. [PMID: 32096268 DOI: 10.1111/jvh.13281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
47 Valerio H, Alavi M, Law M, Tillakeratne S, Amin J, Janjua NZ, Krajden M, George J, Matthews GV, Hajarizadeh B, Degenhardt L, Grebely J, Dore GJ. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. J Hepatol 2021;74:293-302. [PMID: 32931879 DOI: 10.1016/j.jhep.2020.08.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
49 Lazarus JV, Herranz A, Picchio CA, Villota-Rivas M, Rodríguez A, Alonso JM, Moratinos A, Perrotta A, Tegeo E, Bibiloni F, Buti M, Vilella À. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. BMJ Open 2021;11:e053394. [PMID: 34675021 DOI: 10.1136/bmjopen-2021-053394] [Reference Citation Analysis]
50 Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-basantas J, de la Iglesia A, Fuentes J, Pineda JA, Téllez F, Bernal E, Rincón P, Von Wichman MA, Fuentes A, Vera F, Rivero-juárez A, Jiménez M, Vandamme A, García F. Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. Journal of Hepatology 2019;71:1270-2. [DOI: 10.1016/j.jhep.2019.08.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Lens S, Torres F, Bonacci M, Bartres C, Pocurull A, Mariño Z, Londoño MC, Rodríguez-Tajes S, Forns X. Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. Dig Liver Dis 2019;51:875-81. [PMID: 30558865 DOI: 10.1016/j.dld.2018.11.019] [Reference Citation Analysis]
52 Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M. Global hepatitis C elimination: an investment framework. Lancet Gastroenterol Hepatol 2020;5:927-39. [PMID: 32730786 DOI: 10.1016/S2468-1253(20)30010-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
53 Treviño H 2nd, Romero Arenas MA. Systematic Review of Blood-Borne Pathogen Exposure Rates Among Medical Students. J Surg Res 2020;255:66-70. [PMID: 32543380 DOI: 10.1016/j.jss.2020.05.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Pawlotsky J, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis 2020;40:392-402. [DOI: 10.1055/s-0040-1713657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
55 Greenaway C, Castelli F. Migration Medicine. Infect Dis Clin North Am 2019;33:265-87. [PMID: 30712766 DOI: 10.1016/j.idc.2018.10.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
56 Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a Public Health Perspective. Curr Treat Options Gastro 2019;17:367-77. [DOI: 10.1007/s11938-019-00240-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
57 Steininger L, Chromy D, Bauer D, Simbrunner B, Binter T, Schwabl P, Schmidbauer C, Trauner M, Gschwantler M, Mandorfer M, Reiberger T. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. Wien Klin Wochenschr 2021;133:452-60. [PMID: 33351152 DOI: 10.1007/s00508-020-01790-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]